NCT05424016View on ClinicalTrials.gov

Propranolol and Von Hippel-Lindau Disease

NARecruitingINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

January 16, 2023

Primary Completion Date

November 1, 2026

Study Completion Date

November 1, 2026

Conditions
Hemangioblastoma of CNSVon Hippel-Lindau Disease
Interventions
DRUG

Propranolol

120 mg/d propranolol started in a progressive way (with control of Blood Pressure and heart rate during the consultations) neurosurgical consultation and an MRI every six months

OTHER

follow-up

routine follow-up (neurosurgical consultation and an MRI every six months)

Trial Locations (1)

94275

RECRUITING

AP-HP, Bicêtre Hospital, Le Kremlin-Bicêtre

All Listed Sponsors
collaborator

Agence Générale des Equipements et Produits de Santé

OTHER

lead

Assistance Publique - Hôpitaux de Paris

OTHER